Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature

Pharmacotherapy

Volumn 29, Issue 4, 2009, Pages 473-478

  Wong, Michael K K ^a   Jarkowski III, Anthony ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cardiotoxicity; Heart failure; Metastatic renal cell carcinoma; Sorafenib; Sunitinib; Targeted agents; Tyrosine kinase inhibitor

Indexed keywords

CARVEDILOL; FUROSEMIDE; LISINOPRIL; LOPERAMIDE; OMEPRAZOLE; SORAFENIB; SUNITINIB;

ACUTE HEART FAILURE; AGED; ANAMNESIS; ARTICLE; CASE REPORT; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY CARCINOMA; PLEURA EFFUSION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HUMANS; INDOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES;

EID: 64849114033     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.4.473     Document Type: Article

References (30)

1. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-17.
2. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006;33:2-14.
3. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006;6:1249-69.
4. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
7. Xu X, Li J, Simons M, Laham RJ, Sellke FW. Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thorac Cardiovasc Surg 2001;121:735-42.
8. Ayach BB, Yoshimitsu M, Dawood F, et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A 2006;103:2304-9.
9. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006;116:1865-77.
10. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest 2006;116:237-48.
11. Liu J, Wu LL, Li L, Zhang L, Song ZE. Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes. Regul Pept 2005;127:11-18.
12. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112:2500-8.
13. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19:1613-18.
14. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
16. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-42.
17. Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinibpretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007;18:1906-7.
18. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β;-darabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004;10:3577-85.
19. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-19.
20. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44.
21. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2007;368:1329-38.
22. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
23. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2008;117:e25-146.
24. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation 2002;106:3068-72.
25. Machiels JP, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L. Acute cardiac failure after sunitinib. Ann Oncol 2008;19:598-9.
26. Pfizer Inc. Sutent (sunitinib maleate) package insert. New York, NY; 2008.
27. Kerkula R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.
28. Bristol-Myers Squibb Company. Sprycel (dasatinib) package insert. Princeton, NJ; 2008.
29. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, March 31, 2003. Available from http://ctep.cancer.gov Accessed October 1, 2008.
30. Shenoy M, Goldman J. Hypothyroid cardiomyopathy: echocardiographic documentation of reversibility. Am J Med Sci 1987;294:1-9.